Plasma pentosidine: A potential biomarker in the management of multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 2, 2011, Pages 157-163

  Sternberg, Zohara ^a   Hennies, Cassandra ^a   Sternberg, Daniel ^a   Bistulfi, Gaia L ^b   Kazim, Latif ^b   Benedict, Ralph H B ^a   Chadha, Kailash ^b   Leung, Christopher ^a   Weinstock Guttman, Bianca ^a   Munschauer, Frederick ^a  

^a JACOBS NEUROLOGICAL INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

advanced glycation; disease modifying therapies; fluorescent; high pressure liquid chromatography pentosidine; plasma biomarkers

Indexed keywords

BETA INTERFERON; GLATIRAMER; NATALIZUMAB; PENTOSIDINE;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; MULTIPLE SCLEROSIS SEVERITY SCALE; PENTOSIDINE BLOOD LEVEL; RATING SCALE; RELAPSE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TREATMENT OUTCOME;

EID: 79951519138     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510384123     Document Type: Article

References (37)

1. Odetti P., Aragno I., Garibaldi S., Valentini S., Pronzato MA and Rolandi R. Role of advanced glycation end products in aging collagen. Gerontology 1998 ; 44: 187-191.
2. Miyata T., Ueda Y. and Yamada Y. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycosylation end product: carbonyl stress in uremia. J Am Soc Nephrol 1998 ; 9: 2349-2356. (Pubitemid 28543814)
3. Salman AG, Mansour DE, Swelem AH, Al-Zawahary WM and Radwan AA Pentosidine - a new biochemical marker in diabetic retinopathy. Ophthalmic Res 2009 ; 42: 96-98.
4. Koyama Y., Takeishi Y., Arimoto T., Niizeki T., Shishido T., Takahashi H., et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 2007 ; 13: 199-206. (Pubitemid 46590033)
5. Januszewski AS, Alderson NL, Metz TO, Thorpe SR and Baynes JW Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 2003 ; 31: 1413-1416. (Pubitemid 38030989)
6. Grandhee SK and Monnier VM Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991 ; 266: 11649-11653. (Pubitemid 21906998)
7. Dyer DG, Blackledge JA, Thorpe SR and Baynes JW Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991 ; 266: 11654-11660. (Pubitemid 21906999)
8. Vlassara H. Advanced glycation end-products and atherosclerosis. [Review] Ann Med 1996 ; 28: 419-426. (Pubitemid 26380001)
9. Steenvoorden MM, Huizinga TW, Verzijl N., Bank RA, Ronday HK, Luning HA, et al. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum 2006 ; 54: 253-263. (Pubitemid 43122210)
10. Bierhaus A., Haslbeck KM, Morcos M., Schiekofer S., Andrassy M., Chen J., et al. Hyperglycaemia increases CML deposition, RAGE expression and NFkappaB activation in peripheral nerves. Exp Clin Endocrinol Diabetes 2000 ; 108: 122-127.
11. Bucciarelli LG, Wendt T., Rong L., Lalla E., Hofmann MA, Goova MT, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002 ; 59: 1117-1128.
12. Uchimura T., Motomiya Y., Okamura H., Hashiguchi T., Miura M., Uji Y., et al. Marked increases in macrophage colony-stimulating factor and interleukin-18 in maintenance hemodialysis patients: Comparative study of advanced glycation end products, carboxymethyllysine and pentosidine. Nephron 2002 ; 90: 401-407. (Pubitemid 34310103)
13. Karni A., Koldzic DN, Bharanidharan P., Khoury SJ and Weiner HL IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions. J Neuroimmunol 2002 ; 125: 134-140. (Pubitemid 34327462)
14. Szczucinski A., Kalinowska A. and Losy J. CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone. Euro Neurol 2007 ; 58: 228-232. (Pubitemid 350175891)
15. Meerwaldt R., Hartog JW, Graaff R., Huisman RJ, Links TP, den Hollander NC, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005 ; 16: 3687-3693. (Pubitemid 46211290)
16. Hartog JW, Hummel YM, Voors AA, Schalkwijk CG, Miyata T., Huisman RM, et al. Skin autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J Card Fail 2008 ; 14: 596-602.
17. Takeda A., Yasuda T., Miyata T., Goto Y., Wakai M., Watanabe M., et al. Advanced glycation end products co-localized with astrocytes and microglial cells in Alzheimer's disease brain. Acta Neuropathol 1998 ; 95: 555-558.
18. Meli M., Perier C., Ferron C., Parssegny F., Denis C., Gonthier R., et al. Serum pentosidine as an indicator of Alzheimer's disease. J Alzheimers Dis 2002 ; 4: 93-96. (Pubitemid 34578704)
19. Bar KJ, Franke S., Wenda B., Muller S., Kientsch-Engel R., Stein G., et al. Pentosidine and N(epsilon)-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol Aging 2003 ; 24: 333-338. (Pubitemid 36005413)
20. Yan SS, Wu ZY, Zhang HP, Furtado G., Chen X., Yan SF, et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 2003 ; 9: 287-293. (Pubitemid 36362783)
21. Sidoti A., Antognelli C., Rinaldi C., D'Angelo R., Dattola V., Girlanda P., et al. Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis? Mult Scler 2007 ; 13: 446-453. (Pubitemid 46796504)
22. Piwowar A., Knapik-Kordecka M., Szczecinska J. and Warwas M. Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy. Diabetes Metab Res Rev 2008 ; 24: 549-553.
23. Rysava R., Kalousova M., Zima T., Dostal C., Merta M. and Tesar V. Does renal function influence plasma levels of advanced glycation and oxidation protein products in patients with chronic rheumatic diseases complicated by secondary amyloidosis? Kidney Blood Press Res 2007 ; 30: 1-7.
24. Calkin AC, Giunti S., Sheehy KJ, Chew C., Boolell V., Rajaram YS, et al. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia 2008 ; 51: 1731-1740.
25. Miyata T., Ishiguro N., Yasuda Y., Ito T., Nangaku M., Iwata H., et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 1998 ; 244: 45-49. (Pubitemid 28419898)
26. Portaccio E., Zipoli V., Goretti B., De Stefano N. and Amato MP Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci 2009 ; 284: 223-224.
27. Koch M., Mostert J., Arutjunyan AV, Stepanov M., Teelken A., Heersema D., et al. Plasma lipid peroxidation and progression of disability in multiple sclerosis. Euro J Neurol 2007 ; 14: 529-533. (Pubitemid 46587841)
28. Clynes R. and Moser B. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med 2007 ; 7: 743-751.
29. Nienhuis HL, Westra J., Smit AJ, Limburg PC, Kallenberg CG and Bijl M. AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis. [Review] Autoimmunity 2009 ; 42: 302-304.
30. Ochi H., Osoegawa M., Wu XM, Minohara M., Horiuchi I. and Murai H. Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase. J Neurol Sci 2002 ; 201: 45-51. (Pubitemid 34876904)
31. Wheeler TT, Jordan TW and Ford HC Double-label two-dimensional electrophoresis of serum and plasma proteins from patients with multiple sclerosis. J Neurol Sci 1987 ; 78: 87-92. (Pubitemid 17014620)
32. Figarola JL, Shanmugam N., Natarajan R. and Rahbar S. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 2007 ; 56: 647-655. (Pubitemid 46348459)
33. Tanimoto M., Gohda T., Kaneko S., Hagiwara S., Murakoshi M., Aoki T., et al. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism Clin Exp 2007 ; 56: 160-167. (Pubitemid 46074060)
34. Forbes JM, Soulis T., Thallas V., Panagiotopoulos S., Long DM, Vasan S., et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001 ; 44: 108-114. (Pubitemid 32141892)
35. Soulis T., Cooper M., Vranes D., Bucala R. and Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 1996 ; 50: 627.
36. Vasan S., Foiles P. and Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. [Review] Arch Biochem Biophys 2003 ; 419: 89-96. (Pubitemid 37272162)
37. Munch G., Deuther-Conrad W. and Gasic-Milenkovic J. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease - a target for neuroprotective treatment strategies? [Review]. J Neural Transm Suppl 2002 ; 62: 303-307. (Pubitemid 37046674)